DYN Dyne Therapeutics

Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit , and follow us on ,  and .

Contact:

Dyne Therapeutics

Amy Reilly



857-341-1203



EN
27/09/2022

Underlying

DYNDyne Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dyne Therapeutics

 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 tria...

2h / 12m 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Dyne Therapeutics to Participate in Upcoming Investor Conferences WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, fireside chat on Wednesday, March 4, 2026 at 11:50 a.m. ET in Boston, MA2026 Jefferies Biotech on the Beach Summit, hosting meetings on Tuesday, March 10 and Wednesday, Mar...

February 25, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscula...

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase 3 trial design for z-basivarsen in DM1 - - Five total presentations across three neuromuscular diseases demonstrate strength of Dyne’s pipeline based on clinically-validated FORCE™ platform - WALTHAM, Mass., Feb. 22, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on delivering fun...

February 22, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleci...

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE Registrational Expansion Cohort in early Q2 2026 - WALTHAM, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today annou...

January 20, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Con...

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors & Media section of Dyne’s website at...

January 7, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch